TPO and Thrombocytopenia: Two other TPO-RAs have been recently approved, namely avatrombopag (Doptelet®) and lusutrombopag (Mulpleo®), specifically licensed for the treatment of patients with thrombocytopenia secondary to chronic liver disease undergoing invasive procedures (5, 6).